266 related articles for article (PubMed ID: 11419566)
1. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
Cummings JL; Nadel A; Masterman D; Cyrus PA
J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
[TBL] [Abstract][Full Text] [Related]
2. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
3. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
4. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
Farlow MR; Cyrus PA
Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
[TBL] [Abstract][Full Text] [Related]
5. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
6. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
[TBL] [Abstract][Full Text] [Related]
7. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
Kaufer D
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():8-14. PubMed ID: 9718229
[TBL] [Abstract][Full Text] [Related]
8. Metrifonate for Alzheimer's disease.
López-Arrieta JM; Schneider L
Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
10. Metrifonate treatment of AD: influence of APOE genotype.
Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
[TBL] [Abstract][Full Text] [Related]
12. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
McKeith IG
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
[TBL] [Abstract][Full Text] [Related]
13. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
Gélinas I; Gauthier S; Cyrus PA
J Geriatr Psychiatry Neurol; 2000; 13(1):9-16. PubMed ID: 10753002
[TBL] [Abstract][Full Text] [Related]
14. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.
Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
Alzheimer Dis Assoc Disord; 1998 Mar; 12(1):54-7. PubMed ID: 9539412
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
16. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.
Herrmann N; Rabheru K; Wang J; Binder C
Am J Geriatr Psychiatry; 2005 Jun; 13(6):527-34. PubMed ID: 15956273
[TBL] [Abstract][Full Text] [Related]
17. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Ames D; Subbiah P; Whalen E; Emir B;
Int Psychogeriatr; 2002 Dec; 14(4):389-404. PubMed ID: 12670060
[TBL] [Abstract][Full Text] [Related]
19. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.
Shikiar R; Shakespeare A; Sagnier PP; Wilkinson D; McKeith I; Dartigues JF; Dubois B
J Am Geriatr Soc; 2000 Mar; 48(3):268-74. PubMed ID: 10733052
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Fullerton T; Binneman B; David W; Delnomdedieu M; Kupiec J; Lockwood P; Mancuso J; Miceli J; Bell J
Alzheimers Res Ther; 2018 Apr; 10(1):38. PubMed ID: 29622037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
